Xintela has entered into an agreement to raise a convertible loan of SEK 30 million from the Company’s principal shareholder, Flerie Invest, to accelerate the development of XSTEM® for the treatment of osteoarthritis, to repay the previous loan from Fenja Capital II and to meet the Company’s general working capital requirements.
Xintela AB (publ) (“Xintela” or “the Company”) has today entered into an agreement to raise a convertible loan of SEK 30 million from the Company’s principal shareholder, Flerie Invest AB (“Flerie”). The convertible loan will be used to accelerate the development of XSTEM for the treatment of osteoarthritis, to repay in full and ahead of schedule the SEK 20 million loan that the Company raised from Fenja Capital II A/S in November 2025, and to meet the Company’s general working capital requirements.
The convertible loan matures on 25 June 2027 and bears interest at an annual rate of five per cent. Xintela is entitled to repay the loan, in full or in part, including interest, early, provided that Xintela gives Flerie written notice of this at least 20 banking days in advance, in which case Flerie is entitled during this period to request conversion of the loan instead. Flerie is entitled at any time during the term of the loan to convert the loan, in full or in part, into shares in the Company at a conversion price corresponding to the volume-weighted average price of Xintela’s share on the Nasdaq First North Growth Market on 25 June 2026 (the “Conversion Price”).
Furthermore, the entire outstanding convertible loan shall be automatically converted into shares in the Company in the event that the Company carries out a capital raising that raises a total of at least MSEK 60, in which case the conversion price shall be the lower of (i) the Conversion Price and (ii) 75 per cent of the price per share in such capital raising. Conversion under the convertible loan agreement shall, where applicable, take place through Xintela carrying out a private placement of shares to Flerie, which shall be entitled to pay for the subscribed shares by setting off the claim under the convertible loan. As Xintela’s Chairman of the Board, Thomas Eldered, has a controlling influence in Flerie, such a new issue is subject to the so-called LEO rules in Chapter 16 of the Companies Act, and a resolution on the issue must therefore be passed or approved by the general meeting with a majority of at least nine-tenths.
Comment from Xintela’s CEO, Evy Lundgren-Åkerlund
“It is very gratifying that we continue to enjoy the trust from our main owner Flerie Invest. In our strategy going forward, we are fully focused on accelerating the development of our stem cell product XSTEM for the treatment of knee osteoarthritis and we are working on various opportunities to accelerate XSTEM’s way to osteoarthritis patients and to revenues for Xintela. Our strong clinical results with XSTEM in knee osteoarthritis, showing significant reduction in pain and improvement of joint function and that XSTEM stops cartilage degradation and improves the quality of cartilage and bone tissues, put us in an excellent position to continue building value in XSTEM for Xintela and for our shareholders. The loan gives us time to optimise our strategy and secure continued financing to achieve our goals.”
Comment from Flerie’s CEO, Ted Fjällman
“Xintela has reported very good clinical results for XSTEM, and we are optimistic about the Company’s continued development. The convertible loan strengthens the Company’s financial flexibility and provides better conditions for driving forward the prioritised activities in the XSTEM programme.”
For Further information please contact:
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO Tel: +46 46 275 65 00
Email:evy@xintela.se Medicon Village
223 81 Lund www.xintela.se
This information is information that Xintela AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication, through the above-mentioned contact persons, on 25 June 2026 at 21:28 CEST.
AboutXintela
Xintela (XINT) is a listed clinical-stage biopharmaceutical company developing pioneering medical products in the fields of stem cell therapy and targeted cancer therapy. Xintela’s patented technology utilises the stem cell marker integrin α10β1 to select and quality-assure the stem cell product XSTEM®, which has demonstrated safety and disease-modifying effect in a clinical trial for knee osteoarthritis, as well as safety in a clinical trial for difficult-to-heal leg ulcers. Xintela’s own GMP facility manufactures XSTEM for clinical trials and provides process development and manufacturing services for other cell therapies. Xintela’s wholly-owned subsidiary, Targinta AB, is developing first-in-class therapeutic antibodies targeting integrin α10β1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers. Targinta has entered into a collaboration with Memorial Sloan Kettering Cancer Centre in New York. Xintela operates from Medicon Village in Lund and is listed on the Nasdaq First North Growth Market in Stockholm. Xintela’s Certified Adviser is Västra Hamnen Corporate Finance AB.
